China Resources Double-Crane Pharmaceutical (600062) Fundamentals 2026 — P/E 10.9x, Revenue Analysis | SniperIQ
China Resources Double-Crane Pharmaceutical (600062) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥17.8B, trading at ¥17.16 on the SHH. This SniperIQ fundamentals page covers China Resources Double-Crane Pharmaceutical's valuation (P/E 10.9x, P/B 1.5x), profitability (net margin 15.1%), revenue (¥11.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Resources Double-Crane Pharmaceutical's market cap?
China Resources Double-Crane Pharmaceutical (600062) has a market capitalization of approximately ¥17.8B, trading at ¥17.16 on the SHH. Market cap moves with the live share price.
What is China Resources Double-Crane Pharmaceutical's P/E ratio?
China Resources Double-Crane Pharmaceutical's trailing twelve-month P/E ratio is 10.9x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Resources Double-Crane Pharmaceutical?
China Resources Double-Crane Pharmaceutical runs a net profit margin of 15.1%, a gross margin of 57.6%, and an operating margin of 16.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Resources Double-Crane Pharmaceutical generate?
China Resources Double-Crane Pharmaceutical reported revenue of ¥11.0B for fiscal year 2025, with net income of ¥1.6B and earnings per share (EPS) of 1.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Resources Double-Crane Pharmaceutical pay a dividend?
China Resources Double-Crane Pharmaceutical offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Resources Double-Crane Pharmaceutical financially healthy?
China Resources Double-Crane Pharmaceutical carries a debt-to-equity ratio of 0.14x and a current ratio of 2.67x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Resources Double-Crane Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Resources Double-Crane Pharmaceutical (600062) the key facts are: market cap ¥17.8B, P/E 10.9x, revenue ¥11.0B, 52-week range 15.29-22.14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Resources Double-Crane Pharmaceutical's full fundamentals live
Get China Resources Double-Crane Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.